{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:01:14Z","timestamp":1760299274466},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.phrs.2015.12.031","type":"journal-article","created":{"date-parts":[[2015,12,30]],"date-time":"2015-12-30T13:15:39Z","timestamp":1451481339000},"page":"186-196","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic"],"prefix":"10.1016","volume":"104","author":[{"given":"Matteo","family":"Fornai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocchina","family":"Colucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Tirotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Bartalucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Flaibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Renzulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Ghelardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Blandizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Scarpignato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2015.12.031_bib0005","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJM199106133242407","article-title":"Nonsteroidal anti-inflammatory drugs\u2014differences and similarities","volume":"324","author":"Brooks","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.12.031_bib0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1399-6576.1998.tb05083.x","article-title":"Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review","volume":"42","author":"Tram\u00e8r","year":"1998","journal-title":"Acta Anaesthesiol. Scand."},{"key":"10.1016\/j.phrs.2015.12.031_bib0015","series-title":"Meyler\u2019s Side Effects of Analgesics and Anti-Inflammatory Drugs","author":"Aronson","year":"2009"},{"key":"10.1016\/j.phrs.2015.12.031_bib0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/07853890600925843","article-title":"Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies","volume":"38","author":"Lanas","year":"2006","journal-title":"Ann. Med."},{"key":"10.1016\/j.phrs.2015.12.031_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gtc.2010.08.010","article-title":"Nonsteroidal anti-inflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention","volume":"39","author":"Scarpignato","year":"2010","journal-title":"Gastroenterol. Clin. North Am."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0030","first-page":"S63","article-title":"Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds","volume":"31","author":"Scarpignato","year":"1999","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0035","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12916-015-0285-8","article-title":"International NSAID Consensus Group. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis\u2014an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks","volume":"13","author":"Scarpignato","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.phrs.2015.12.031_bib0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","article-title":"Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial","volume":"123","author":"Silverstein","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.phrs.2015.12.031_bib0045","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/gast.2003.50054","article-title":"Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use","volume":"124","author":"Laine","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2015.12.031_bib0050","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/ajg.2009.164","article-title":"Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice","volume":"104","author":"Lanas","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1542-3565(04)00603-2","article-title":"Visible small-intestinal mucosal injury in chronic NSAID users","volume":"3","author":"Graham","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0060","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1053\/j.gastro.2005.03.020","article-title":"A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy","volume":"128","author":"Maiden","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2015.12.031_bib0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2362.2010.02290.x","article-title":"Distribution of small intestinal mucosal injuries as a result of NSAID administration","volume":"40","author":"Fujimori","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.phrs.2015.12.031_bib0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1542-3565(04)00619-6","article-title":"Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo","volume":"3","author":"Goldstein","year":"2005","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0075","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/j.1365-2036.2007.03312.x","article-title":"Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy","volume":"25","author":"Goldstein","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0080","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3748\/wjg.v19.i12.1861","article-title":"Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy","volume":"19","author":"Wallace","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0085","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/den.12188","article-title":"Omeprazole increased small intestinal mucosal injury in two of six disease-free cases evaluated by capsule endoscopy","volume":"26","author":"Fujimori","year":"2014","journal-title":"Dig. Endosc."},{"key":"10.1016\/j.phrs.2015.12.031_bib0090","article-title":"Proton pump inhibitors exacerbate NSAID-induced small bowel injury: A prospective, double-blind, randomized trial","author":"Washio","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/gut.2007.134502","article-title":"NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?","volume":"57","author":"Scarpignato","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2015.12.031_bib0100","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/bega.2001.0231","article-title":"Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine","volume":"15","author":"Smale","year":"2001","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2036.2007.03348.x","article-title":"Determinants of the short-term gastric damage caused by NSAIDs in man","volume":"26","author":"Bjarnason","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0110","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00535-009-0102-2","article-title":"Present status and strategy of NSAIDs-induced small bowel injury","volume":"44","author":"Higuchi","year":"2009","journal-title":"J. Gastroenterol."},{"issue":"Suppl. 19","key":"10.1016\/j.phrs.2015.12.031_bib0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00535-008-2266-6","article-title":"Intestinal permeability in the pathogenesis of NSAID-induced enteropathy","volume":"44","author":"Bjarnason","year":"2009","journal-title":"J. Gastroenterol."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0120","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000089789","article-title":"Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?","volume":"73","author":"Lanas","year":"2006","journal-title":"Digestion"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0125","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.phrs.2015.12.031_bib0130","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3748\/wjg.v19.i6.889","article-title":"Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy","volume":"19","author":"R\u00e1cz","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0135","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/gut.33.9.1204","article-title":"Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy","volume":"33","author":"Bjarnason","year":"1992","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2015.12.031_bib0140","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2165\/00003495-199754050-00003","article-title":"Metronidazole: a therapeutic review and update","volume":"54","author":"Freeman","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2015.12.031_bib0145","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1021\/jm00145a020","article-title":"4-Deoxypyrido[1\u2032,2\u2032:1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption","volume":"28","author":"Marchi","year":"1985","journal-title":"J. Med. Chem."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","article-title":"Rifaximin: in vitro and in vivo antibacterial activity\u2014review","volume":"51","author":"Jiang","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.phrs.2015.12.031_bib0155","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ja.2014.106","article-title":"Rifaximin: beyond the traditional antibiotic activity","volume":"67","author":"Calanni","year":"2014","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0160","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000089776","article-title":"Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic","volume":"73","author":"Scarpignato","year":"2006","journal-title":"Digestion"},{"key":"10.1016\/j.phrs.2015.12.031_bib0165","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.gastro.2011.11.032","article-title":"Retic study group (Rifaximin-EIR treatment in Crohn\u2019s disease). Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn\u2019s disease","volume":"142","author":"Prantera","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2015.12.031_bib0170","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1056\/NEJM199306243282507","article-title":"Prevention and treatment of traveler\u2019s diarrhea","volume":"328","author":"DuPont","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2015.12.031_bib0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/jpet.113.207118","article-title":"NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?","volume":"348","author":"Fornai","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF01964912","article-title":"An X-ray analysis of adjuvant arthritis in the rat. The effect of prednisolone and indomethacin","volume":"7","author":"Blackham","year":"1977","journal-title":"Agents Actions"},{"key":"10.1016\/j.phrs.2015.12.031_bib0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(99)00931-3","article-title":"Inhibition of carrageenan-induced edema by indomethacin or sodium salicylate does not prevent the increase of nerve growth factor in the rat hind paw","volume":"278","author":"Amann","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2015.12.031_bib0190","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1006\/phrs.2001.0869","article-title":"Effects of daily oral administration of rifaximin and neomycin on faecal aerobic flora in rats","volume":"44","author":"Miglioli","year":"2001","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.12.031_bib0195","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s10753-012-9465-2","article-title":"Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats","volume":"35","author":"Harputluoglu","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2015.12.031_bib0200","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjp.0701968","article-title":"Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine","volume":"124","author":"Bertrand","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0205","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1124\/jpet.107.122762","article-title":"Inhibition of adenosine deaminase attenuates inflammation in experimental colitis","volume":"322","author":"Antonioli","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0210","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0009-8981(03)00003-2","article-title":"Protein carbonyl groups as biomarkers of oxidative stress","volume":"329","author":"Dalle-Donne","year":"2003","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.phrs.2015.12.031_bib0215","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0076-6879(94)33041-7","article-title":"Oxidative damage to proteins: spectrophotometric method for carbonyl assay","volume":"233","author":"Reznick","year":"1994","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0220","first-page":"344","article-title":"Effects of rifaximin on indomethacin-induced intestinal damage in guinea-pigs","volume":"18","author":"Ciobanu","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.phrs.2015.12.031_bib0225","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2036.2012.05213.x","article-title":"Risk factors associated with a decrease >\/=2g\/dL in haemoglobin and\/or >\/=10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR)","volume":"36","author":"Lanas","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0230","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.dld.2012.12.005","article-title":"Risk factors for severe nonsteroidal anti-inflammatory drug-induced small intestinal damage","volume":"45","author":"Watanabe","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.phrs.2015.12.031_bib0235","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2036.1995.tb00398.x","article-title":"Intestinal site-dependent susceptibility to chronic indomethacin in the rat: a morphological and biochemical study","volume":"9","author":"Nyg\u00e5rd","year":"1995","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.lfs.2013.07.021","article-title":"Roles of pro-angiogenic and anti-angiogenic factors as well as matrix metalloproteinases in healing of NSAID-induced small intestinal ulcers in rats","volume":"93","author":"Gyenge","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2015.12.031_bib0245","doi-asserted-by":"crossref","first-page":"429706","DOI":"10.1155\/2013\/429706","article-title":"Emu oil reduces small intestinal inflammation in the absence of clinical improvement in a rat model of indomethacin-induced enteropathy","volume":"2013","author":"Abimosleh","year":"2013","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"10.1016\/j.phrs.2015.12.031_bib0250","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.3748\/wjg.v20.i10.2641","article-title":"Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats","volume":"20","author":"Yamamoto","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0255","first-page":"387","article-title":"A non-absorbable rifamycin for treatment of hepatic encephalopathy","volume":"11","author":"Testa","year":"1985","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.phrs.2015.12.031_bib0260","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF00583700","article-title":"Actions of prostaglandins and indomethacin on the electrical and mechanical properties of smooth muscle cells of the guinea-pig ileocecal junction","volume":"394","author":"Kubota","year":"1982","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.phrs.2015.12.031_bib0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0014-2999(84)90379-0","article-title":"Possible involvement of a product of the 5-lipoxygenase pathway in mediation of indomethacin-induced inhibition of cholinergic transmission in guinea-pig ileum","volume":"104","author":"Nakahata","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0270","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/sj.bjp.0703940","article-title":"Disturbance of peristalsis in the guinea-pig isolated small intestine by indomethacin, but not cyclo-oxygenase isoform-selective inhibitors","volume":"132","author":"Shahbazian","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0090-6980(77)90178-2","article-title":"Resistance of germ free rats to indomethacin-induced lesions","volume":"14","author":"Robert","year":"1977","journal-title":"Prostaglandins"},{"key":"10.1016\/j.phrs.2015.12.031_bib0280","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s10620-006-8045-4","article-title":"Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs","volume":"51","author":"Takeuchi","year":"2006","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2015.12.031_bib0285","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1006\/phrs.1997.0194","article-title":"Toxicokinetics of indomethacin-induced intestinal permeability in the rat","volume":"35","author":"Wright","year":"1997","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2015.12.031_bib0290","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/gut.2007.125963","article-title":"Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent","volume":"57","author":"Watanabe","year":"2008","journal-title":"Gut"},{"issue":"Suppl. 4","key":"10.1016\/j.phrs.2015.12.031_bib0295","first-page":"165","article-title":"Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage","volume":"54","author":"Takeuchi","year":"2003","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0300","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/00365521.2014.880182","article-title":"Role of small intestinal bacterial overgrowth in severe small intestinal damage in chronic non-steroidal anti-inflammatory drug users","volume":"49","author":"Muraki","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0305","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/apt.12531","article-title":"Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth","volume":"38","author":"Scarpignato","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0310","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/apt.12479","article-title":"Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth","volume":"38","author":"Shah","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"Suppl. 5","key":"10.1016\/j.phrs.2015.12.031_bib0315","article-title":"Rifaximin prevents enteric bacteria alterations and inflammation in a rat model of diclofenac-induced enteropathy","volume":"5","author":"Colucci","year":"2015","journal-title":"United European Gastroenterol. J."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0320","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0016-5085(15)30236-5","article-title":"Rifaximin for prevention of NSAID-associated intestinal lesions in healthy volunteers: a randomized, double-blind, placebo-controlled, video-capsule study","volume":"148","author":"Scarpignato","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2015.12.031_bib0325","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10620-013-2675-0","article-title":"The effect of rifaximin on gut flora and Staphylococcus resistance","volume":"58","author":"Kim","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2015.12.031_bib0330","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2015.12.031_bib0335","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.111.191122","article-title":"Pharmacologic targeting of bacterial \u03b2-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice","volume":"341","author":"LoGuidice","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2015.12.031_bib0340","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3109\/00498254.2013.811314","article-title":"Bacterial \u03b2-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics","volume":"44","author":"Saitta","year":"2014","journal-title":"Xenobiotica"},{"key":"10.1016\/j.phrs.2015.12.031_bib0345","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1027314419843","article-title":"Rifamycins inhibit human neutrophil functions: new derivatives with potential antiinflammatory activity","volume":"21","author":"Spisani","year":"1997","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2015.12.031_bib0350","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/A:1022341909396","article-title":"3-(Carboxyalkylthio) rifamycin S and SV derivatives inhibit human neutrophil functions","volume":"22","author":"Spisani","year":"1998","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2015.12.031_bib0355","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/030006059702500601","article-title":"Twenty years of experience with intra-articular rifamycin for chronic arthritides","volume":"25","author":"Caruso","year":"1997","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.phrs.2015.12.031_bib0360","first-page":"676","article-title":"Oxidation of a metabolite of indomethacin (desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system","volume":"26","author":"Ju","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.phrs.2015.12.031_bib0365","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/jac\/dkq345","article-title":"Rifaximin modulates the colonic microbiota of patients with Crohn\u2019s disease: an in vitro approach using a continuous culture colonic model system","volume":"65","author":"Maccaferri","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"Suppl","key":"10.1016\/j.phrs.2015.12.031_bib0370","first-page":"A138","article-title":"Rifaximin treatment increases Lactobacillus abudance in patients with different gastrointestinal and liver diseases","volume":"3","author":"Ponziani","year":"2015","journal-title":"United European Gastroenterol. J."},{"key":"10.1016\/j.phrs.2015.12.031_bib0375","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00535-014-1032-1","article-title":"NSAID enteropathy and bacteria: a complicated relationship","volume":"50","author":"Syer","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.phrs.2015.12.031_bib0380","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2015.12.031_bib0385","doi-asserted-by":"crossref","first-page":"S-655","DOI":"10.1016\/S0016-5085(15)32213-7","article-title":"Characterization of stool microbiota in subjects with IBS-D receiving repeat treatments with rifaximin in the TARGET 3 study","volume":"148","author":"Pimentel","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815002960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661815002960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T08:54:48Z","timestamp":1537088088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661815002960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":77,"alternative-id":["S1043661815002960"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2015.12.031","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2015.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}